SG/PUT/VERTEX PHARMACEUTICALS/400/0.1/21.03.25 | Real-time Boerse Frankfurt Warrants 16:21:59 03/07/2024 BST | ||
| 1.44 EUR | +4.35% |
|
| Current month | -4.83% | ||
| 1 month | -28.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 1.44 | +4.35% |
| 02/07/24 | 1.38 | -6.12% |
| 01/07/24 | 1.47 | +1.38% |
| 28/06/24 | 1.45 | +3.57% |
| 27/06/24 | 1.4 | -2.10% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 04:21 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6Q3P |
| ISIN | DE000SU6Q3P2 |
| Date issued | 08/01/2024 |
| Strike | 400 $ |
| Maturity | 21/03/2025 (261 Days) |
| Parity | 10 : 1 |
| Emission price | 3.7 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.17 € |
|---|---|
| Lowest since issue | 1.32 € |
| Spread | 0.03 € |
| Spread % | 2.01% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
468.3
USD
Spread / Average Target
-1.16%
- Stock Market
- Warrants
- Warrant
